Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma

Molecular Medicine Reports

Volumn 5, Issue 4, 2012, Pages 1033-1036

  Lu, Bei Ji ^a,b   Wang, Yun Qing ^b   Wei, Xue Jie ^b   Rong, Liang Qun ^b   Wei, Dong ^b   Yan, Chang Ming ^b   Wang, Deng Jie ^b   Sun, Jun Ying ^a  

^a SOOCHOW UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathological parameter; Immunohistochemistry; Osteosarcoma; Ror2; Wnt 5a

Indexed keywords

PEPTIDES AND PROTEINS; PROTEIN ROR2; UNCLASSIFIED DRUG; WNT5A PROTEIN;

ADULT; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DISEASE SEVERITY; ENNEKING SURGICAL STAGE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; OSTEOCHONDROMA; OSTEOSARCOMA; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; BONE NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM METASTASIS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS; YOUNG ADULT;

EID: 84863270637     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.772     Document Type: Article

References (21)

1. Unni KK: Osteosarcoma of bone. J Orthop Sci 3: 287-294, 1998.
2. Lewis VO: What's new in musculoskeletal oncology. J Bone Joint Surg Am 91: 1546-1556, 2009.
3. Wafa H and Grimer RJ: Surgical options and outcomes in bone sarcoma. Expert Rev Anticancer Ther 6: 239-248, 2006. (Pubitemid 44192935)
4. Meyers PA, Schwartz CL, Krailo MD, et al: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 26: 633-638, 2008. (Pubitemid 351264359)
5. Yao H, Ashihara E and Maekawa T: Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets 15: 873-887, 2011.
6. Sylvie J, Ellen C and Kris V: The role of Wnt in cell signaling and cell adhesion during early vertebrate development. Front Biosci 17: 2352-2366, 2011.
7. Clark CC, Cohen I, Eichstetter I, Cannizzaro LA, McPherson JD, Wasmuth JJ and Iozzo RV: Molecular cloning of the human proto-oncogene Wnt-5A and mapping of the gene (WNT5A) to chromosome 3p14-p21. Genomics 18: 249-260, 1993. (Pubitemid 23339534)
8. Pukrop T and Binder C: The complex pathways of Wnt 5a in cancer progression. J Mol Med (Berl) 86: 259-266, 2008. (Pubitemid 351311422)
9. McDonald SL and Silver A: The opposing roles of Wnt-5a in cancer. Br J Cancer 101: 209-214, 2009.
10. Dejmek J, Dejmek A, Säfholm A,Sjölander A and Andersson T: Wnt-5a protein expression in primary Dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 65: 9142-9146, 2005. (Pubitemid 41507974)
11. Kremenevskaja N, von Wasielewski R, Rao AS, Schöfl C, Andersson T and Brabant G: Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24: 2144-2154, 2005. (Pubitemid 40516581)
12. Kurayoshi M, Oue N, Yamamoto H, et al: Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 66: 10439-10448, 2006. (Pubitemid 44799765)
13. Blanc E, Goldschneider D, Douc-Rasy S, Bénard J and Raguénez G: Wnt-5a gene expression in malignant human neuroblasts. Cancer Lett 228: 117-123, 2005. (Pubitemid 41188433)
14. Oishi I, Suzuki H, Onishi N, et al: The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt-5a/JNK signalling pathway. Genes Cells 8: 645-654, 2003. (Pubitemid 36880848)
15. Morioka K, Tanikawa C, Ochi K, et al: Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci 100: 1227-1233, 2009.
16. Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res: 4-18, 2003.
17. Huang CL, Liu D, Nakano J, et al: Wnt-5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor - an expression in non-small-cell lung cancer. J Clin Oncol 23: 8765-8773, 2005. (Pubitemid 46211522)
18. Liu XH, Pan MH, Lu ZF, et al: Expression of Wnt-5a and its clinicopathological significance in hepatocellular carcinoma. Dig Liver Dis 40: 560-567, 2008.
19. Schlessinger J: Cell signaling by receptor tyrosine kinase. Cell 103: 211-225, 2000.
20. Afzral AR and Jeffery S: One gene, two phenotypes: ROR2 mutations in autosomal recessive Robinow syndrome and autosomal dominant brachydactyly type B. Hum Mutat 22: 1- 11, 2003.
21. Mikels AJ and Nusse R: Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 4: e115, 2006.